S 02391 (see companion A 00612) – New York
Introduced: 2019 Status: Inactive / Dead
Requires the commissioner of health to establish and publish a list of generic drug products.
S 06531 (see companion bills A 02836 and S 02087) – New York
Introduced: 2019 Status: Inactive / Dead
Provides for pharmacy benefit management and the procurement of prescription drugs to be dispensed to patients, or the administration or management of prescription drug benefits; sets forth definitions; provides for funds received by a pharmacy …
S 1295 – Massachusetts
Introduced: 2019 Status: Inactive / Dead
For legislation to reduce healthcare costs by promoting non-biased prescriber education. Public Health.
S 1350 (see companion bill A 3693) – New York
Introduced: 2023 Status: Enacted
Relates to brand-name drugs with and without an AB generic equivalent; amends the effective date from January to July next succeeding the date on which it shall have become a law. Sections 1-3 provide that …
S 1465 – Massachusetts
Introduced: 2021 Status: Inactive / Dead
For legislation to reduce healthcare costs by promoting non-biased prescriber education. Public Health.
S 1667 (see companion bill A 2240) – New Jersey
Introduced: 2022 Status: In Process
Prohibits excessive increases in prices charged for essential off-patent and generic prescription drugs and biological products.
S 3048 – New York
Introduced: 2021 Status: In Process
Enacts the “New York affordable drug manufacturing act of 2021” to direct the commissioner of health to enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, …
S 329 (see companion bill A 1747) – New Jersey
Introduced: 2022 Status: In Process
This bill establishes the Prescription Drug Affordability Board (Board), which will be charged with protecting New Jersey residents, State and local governments, health benefits plans, health care providers, licensed pharmacies, and other stakeholders within the …
S 3762 (see companion bill A 1396) – New York
Introduced: 2021 Status: Enacted
Provides for pharmacy benefit management and the procurement of prescription drugs to be dispensed to patients, or the administration or management of prescription drug benefits; sets forth definitions; provides for funds received by a pharmacy …
S 398 (see companion bill A 8824) – New York
Introduced: 2022 Status: In Process
Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.
S 4181 (see companion bill A 144) – New York
Introduced: 2023 Status: In Process
Requires the commissioner of health to establish and publish a list of generic drug products.
S 4370 (see companion bill A 7245) – New York
Introduced: 2021 Status: In Process
Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, is to …
S 463 – South Carolina
Introduced: 2019 Status: Enacted
Amend Section 40-43-86, As Amended, Code Of Laws Of South Carolina, 1976, Relating To Facility Requirements For Pharmacies, The Presence Of Pharmacists-in-charge, Consultant Pharmacists, Prescription Drug Orders, The Transferring Of Prescriptions, The Substitution Of An …
S 4788A (see companion bill A 7509) – New York
Introduced: 2017 Status: Enacted
INTERCHANGEABLE BIOLOGICAL PRODUCTS: Allows a pharmacist to dispense a lower cost generically equivalent drug product or interchangeable biological product.
S 5158 (see companion bill A 1923) – New York
Introduced: 2021 Status: In Process
Requires the commissioner of health to establish and publish a list of generic drug products.
S 5169 (see companion bill A 7196) – New York
Introduced: 2019 Status: Inactive / Dead
Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of agreements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.